Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials

Michael J. Burke(Children's Hospital of Wisconsin), Archie Bleyer(Oregon Health & Science University), Reuven J. Schore(Children's National), Eric Larsen(University of Massachusetts Chan Medical School), Stephen P. Hunger(Children's Hospital of Philadelphia), Elizabeth A. Raetz(NYU Langone Health), Anne Angiolillo(Children's National), Len A. Mattano, Wanda L. Salzer(Maine Medical Center), Kimberly P. Dunsmore(University of Virginia), Stuart S. Winter(New Mexico Cancer Center), Kelly W. Maloney(Children's Hospital Colorado), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Naomi Winick(The University of Texas Southwestern Medical Center), Mignon L. Loh(Seattle Children's Hospital)
Leukemia & lymphoma/Leukemia and lymphoma
November 8, 2017
Cited by 46


Related Papers